Gene Logic Expands ToxExpress Solutions - Launches New Molecular Mechanism of Toxicity Services
New Services Complement Expanding ToxExpress Solutions for Predictive Toxicogenomics
Advertisement
Gene Logic Inc. announced the expansion of its ToxExpress toxicogenomics solutions with the launch of its Molecular Mechanism of toxicity (ToxMOT) services. This new service, as well as the other products and services within Gene Logic's state-of-the-art toxicogenomics program, will be discussed in various forums at the Society of toxicology (SOT) Annual Meeting for 2003.
Gene Logic's ToxExpress Solutions consists of a broad range of gene expression-based products and services that provide a comprehensive and flexible approach to toxicogenomic analysis. The new ToxMOT Services build on the Company's recognized expertise in toxicogenomics and offer researchers a new, solution-oriented analysis service for unraveling and understanding mechanism of toxicity as it relates to drug development.
Gene Logic will conduct studies on customers' specific candidate drugs to determine the "how" and "why" of observed or anticipated toxicity in each compound under analysis. The ToxMOT Services can augment current research efforts spanning the lead optimization through the early clinical phases of development. These services offer Gene Logic's pharmaceutical and biotechnology customers critical insights into the toxic potential of their lead compounds. Specifically, these services will enable researchers to: 1) determine molecular mechanisms being triggered by toxicity; 2) understand biological changes following adverse events; 3) confirm observations or suspicions of toxicity; and 4) facilitate drug development decisions through ranking of compounds based on their mechanism of toxicity.
ToxMOT Services are currently available, under contract agreement, for fees determined by the scope and complexity of the analysis to be conducted.
Commenting on this new service offering, Donna Mendrick, Ph.D., Vice President and Scientific Director for Toxicogenomics at Gene Logic, said, "The launch of our ToxMOT Services is a continuation of our commitment to expand the application of toxicogenomics into the mainstream drug development process.
The objective of our toxicogenomics approach is to enable our customers to better understand and predict human toxicity at an earlier stage, resulting in lower failure rates in the preclinical and early clinical phases of development."
Other news from the department research and development
These products might interest you
Most read news
More news from our other portals
Last viewed contents
Medicyte GmbH Benefits From Multi-Million Euro EU Grant VascuBone
Kill the cancer, not the patient: New toxicity testing approach could make chemo drugs safer - National Cancer Institute grants $1M to test 3 chemo drugs
Pioneering discovery of an odor-detecting receptor enhancer
Modified crops reveal hidden cost of resistance
MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program - First HuCAL-based Antibody to Enter Clinical Trial in Second Indication
Viruses on the run - ETH Zurich Professor Ari Helenius awarded Benoist Prize
New approach in the treatment of non-alcoholic fatty liver disease - Resistant starch, such as that found in green bananas, may play an important role in treatment of non-alcoholic fatty liver disease in the future
